These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2129351)

  • 21. [Aluminum poisoning in renal dialysis patients: bone histology. Value of quantitative bone biopsy].
    Charhon SA; Chapuy MC; Traeger J; Meunier PJ
    Presse Med; 1984 Jun; 13(23):1431-4. PubMed ID: 6233588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis.
    Charhon SA; Chavassieux PM; Meunier PJ; Accominotti M
    Br Med J (Clin Res Ed); 1985 Jun; 290(6482):1613-4. PubMed ID: 3924189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron overload and bone disease in chronic dialysis patients.
    Van de Vyver FL; Visser WJ; D'Haese PC; De Broe ME
    Contrib Nephrol; 1988; 64():134-43. PubMed ID: 3180820
    [No Abstract]   [Full Text] [Related]  

  • 26. Bone aluminum and histomorphometric features of renal osteodystrophy.
    Hodsman AB; Sherrard DJ; Alfrey AC; Ott S; Brickman AS; Miller NL; Maloney NA; Coburn JW
    J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in bone histoquantitative parameters and histochemical staining reactions for aluminium in a group of patients with chronic renal failure following a reduction in the aluminium concentration of the haemodialysis fluid.
    McClure J; Fazzalari NL; Fassett RG; Pugsley PG
    J Clin Pathol; 1984 Jul; 37(7):743-7. PubMed ID: 6747011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of serum aluminium monitoring in dialysis patients: a multicentre study.
    D'Haese PC; Clement JP; Elseviers MM; Lamberts LV; Van de Vyver FL; Visser WJ; De Broe ME
    Nephrol Dial Transplant; 1990; 5(1):45-53. PubMed ID: 2109284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localisation of aluminium by histochemical and electron probe x-ray microanalytical techniques in bone tissue of cases of renal osteodystrophy.
    Smith PS; McClure J
    J Clin Pathol; 1982 Nov; 35(11):1283-93. PubMed ID: 7142436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of aluminium intoxication in long-term acetate Redy dialysis.
    Van de Vyver FL; Visser WJ; D'Haese PC; Silva FJ; Thomas H; De Broe ME
    Nephrol Dial Transplant; 1989; 4(6):555-62. PubMed ID: 2507978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Renal osteodystrophy: aluminium and secondary hyperparathyroidism].
    de Vernejoul MC
    Rev Prat; 1990 Mar; 40(7):613-8. PubMed ID: 2326587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Histochemical localization of aluminum deposits in bones and their relation to the clinical and histomorphometric findings in patients with chronic renal failure].
    Stein G; Herzfeld T; Abendroth K; Günther K; Fünfstück F; Sperschneider H; Michael R
    Z Urol Nephrol; 1986 Oct; 79(10):577-86. PubMed ID: 3811646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histologic evolution of bone disease 6 months after successful kidney transplantation.
    Cruz EA; Lugon JR; Jorgetti V; Draibe SA; Carvalho AB
    Am J Kidney Dis; 2004 Oct; 44(4):747-56. PubMed ID: 15384027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear chromatin-concentrated osteoblasts in renal bone diseases.
    Kazama JJ; Yamamoto S; Narita I; Kurihara S
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():9-13. PubMed ID: 21595845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
    Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of desferrioxamine infusion test for bone aluminium deposits in hemodialyzed patients.
    Berland Y; Charhon SA; Olmer M; Meunier PJ
    Nephron; 1985; 40(4):433-5. PubMed ID: 4022212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal osteodystrophy in CAPD.
    Hutchison AJ; Freemont AJ; Lumb GA; Gokal R
    Adv Perit Dial; 1991; 7():237-9. PubMed ID: 1680434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.